Merck & Co., Inc. (LON:0QAH)

Market Cap	174.11B
Revenue (ttm)	51.26B
Net Income (ttm)	13.67B
Shares Out	n/a
EPS (ttm)	5.38
PE Ratio	12.73
Forward PE	n/a
Dividend	2.45 (2.73%)
Ex-Dividend Date	Mar 17, 2025

Volume	2,180
Average Volume	37,386
Open	89.29
Previous Close	89.70
Day's Range	89.29 - 95.07
52-Week Range	84.53 - 119.56
Beta	0.36
RSI	32.61
Earnings Date	Apr 24, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAH

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD